72 Results for "

Specific uptake

" in MedChemExpress (MCE) Product Catalog:
Products (72)

72 Results for "Specific uptake" in MCE Product Catalog:

Cat. No.: HY-182345
Target:  

CD38

Research Areas:  

Cancer

NOTA-MK0159 is a NOTA (HY-134418) and MK0159 (HY-150508) conjugate. NOTA-MK0159 inhibits human and mouse CD38 with IC50 values of 72.58 and 7.55 nM. NOTA-MK0159 coupled with radioactive elements acts as a imaging agent with specific uptake in CD38-positive multiple myeloma cells, enabling noninvasive whole-body assessment of CD38 expression in multiple myeloma xenografts. NOTA-MK0159 can be used for the research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-181285
Research Areas:  

Cancer

MAT2A ligand 1 is a MAT2A ligand inhibitor (IC50=29.5 nM) and PET tracer that crosses the blood-brain barrier. MAT2A ligand 1 enables non-invasive imaging of MAT2A-expressing tumors, with rapid tumor uptake equilibrium, a high tumor-to-muscle ratio, and specific tumor-binding properties. MAT2A ligand 1 is applicable to research related to non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioblastoma, pancreatic adenocarcinoma, urothelial carcinoma, breast cancer, and prostate cancer .
loading...
    loading...
Cat. No.: HY-182944
CAS No.: 1265900-99-9
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

GATT-44 is a blood-brain barrier-permeable, selective GABA transporter 1 (GAT-1) ligand with an IC50 of 126 nM. GATT-44 shows selectivity for GAT-2, GAT-3 and BGT-1 subtypes, and undergoes copper-mediated 18F-radiofluorination. The radiolabeled GATT-44 ([ 18F]GATT-44) exhibits brain uptake, metabolic stability and high GAT-1 binding specificity in non-human primates. GATT-44 is applicable for research on neurodegenerative and neuropsychiatric diseases .
loading...
    loading...
Cat. No.: HY-N12990
CAS No.: 34328-57-9
Synonyms: MyA
Myrigalone A (MyA) is a plant ethylene biosynthesis inhibitor and natural herbicide . Myrigalone A possesses antioxidant, antifungal, and antimicrobial activities. Myrigalone A interferes with auxin homeostasis during seed germination. Myrigalone A delays seed germination, inhibits the formation of roots, hypocotyls, and root hairs, and causes developmental delay in specific organisms. Myrigalone A triggers the induction of detoxification programs, alters the metabolism of gibberellins, cis-(+)-12-oxophytodienoic acid, and jasmonic acid, disrupts the antioxidant system and oxidative signaling, and impairs the function of aquaporins and water uptake in imbibed seeds. Myrigalone A can be used in studies related to herbicides and plant growth regulators .
loading...
    loading...
Cat. No.: HY-P11863
Target:  

c-Met/HGFR

Research Areas:  

Infection Cancer

SMIC-1014 is a cellular mesenchymal-epithelial transition factor (c-Met) ligand. SMIC-1014 binds to the c-Met ectodomain without activating c-Met phosphorylation or inducing receptor internalization. SMIC-1014, when radiolabeled as [ 68Ga]Ga-SMIC-1014, acts as a positron emission tomography (PET) probe with defined pharmacokinetics, achieves specific tumor uptake in xenografts, and functions as a c-Met-targeted diagnostic probe. SMIC-1014 can be used for the research of colon cancer, hepatocellular carcinoma, prostate cancer .
loading...
    loading...
Cat. No.: HY-P11864
Research Areas:  

Cancer

DOTA-SMIC-1014 is a DOTA chelator-conjugated precursor of the c-Met-targeting peptide SMIC-1014 (HY-P11863). DOTA-SMIC-1014 binds to the extracellular domain of c-Met (Kd = 42.83 nM). After radiolabeling to [ 68Ga]Ga-SMIC-1014, DOTA-SMIC-1014 acts as a positron emission tomography (PET) probe that achieves specific tumor uptake in xenografts and functions as a diagnostic probe targeting c-Met. SMIC-1014 can be used in research related to colon cancer, hepatocellular carcinoma, and prostate cancer .
loading...
    loading...
Cat. No.: HY-182367
Target:  

GPR39

Research Areas:  

Neurological Disease

TMN-OMe is a blood-brain barrier-permeable GPR39 agonist and a radiotracer for positron emission tomography (PET). TMN-OMe activates GPR39 by recruiting β-arrestin, exhibits highly selective binding ability in the mouse brain, and enables quantitative analysis of GPR39 at the in vivo level. TMN-OMe shows specific uptake in GPR39 knockout mice, Alzheimer's disease model (APP/PS1) mice, and blocking experiments. TMN-OMe facilitates in-depth exploration of changes in GPR39-related mechanisms in neurological diseases and is widely used in Alzheimer's disease research .
loading...
    loading...
Cat. No.: HY-182601
CAS No.: 1639784-02-3
Research Areas:  

Neurological Disease

MC-100093 is an orally active, blood-brain barrier-permeable GLT-1 expression upregulator . MC-100093 upregulates the expression of GLT-1 and xCT in rats, and alleviates sedative agent-induced GLT-1 downregulation, IL-6 upregulation and motor hyperactivity. MC-100093 upregulates GLT-1 expression and enhances glutamate uptake in astrocyte-neuron co-culture systems. MC-100093 reduces ethanol consumption and preference, and exerts gender-specific antidepressant-like effects . MC-100093 can be used in studies related to sedative agent overdose, mood disorders and alcohol use disorders .
loading...
    loading...
Cat. No.: HY-120247
CAS No.: 1520893-08-6
Research Areas:  

Others

TASP0434299 (Compound 10) is a labeled ligand for the vasopressin V1b receptor. TASP0434299 exhibits high binding affinity for human and murine V1B receptors, with IC50 values of 0.526 nM and 0.641 nM, respectively, and shows potent antagonistic activity against the human V1B receptor with an IC50 of 0.639 nM. TASP0434299 is a substrate for human and rhesus monkey P-glycoprotein, resulting in low brain uptake in rhesus monkeys. TASP0434299 binds to V1B receptors in rat and monkey pituitary tissues in a saturable and specific manner both in vitro and in vivo. When radiolabeled with tritium or 11C, TASP0434299 serves as a prototype V1B receptor radiotracer to visualize V1B receptor in the pituitary gland of anesthetized monkeys via positron emission tomography .
loading...
    loading...
Cat. No.: HY-L214
227 compounds

Liposomes are spherical or multilayered spherical vesicles formed by the self-assembly of diacyl chain phospholipids (lipid bilayers) in aqueous solutions, which can be made from natural or synthetic phospholipids and exhibit good biocompatibility and low toxicity. They can serve as delivery carriers for various bioactive substances (such as drugs, proteins, nucleic acids, etc.) and are widely used in biomedical and chemical research. The main advantages of liposomes include 1) Protective effect: Their bilayer structure can protect encapsulated molecules from enzymatic degradation, oxidation, and other influences, extending stability and activity; 2) Active targeting: Surface modifications enable active targeting, enhancing the concentration of drugs or molecules in specific tissues or cells; 3) Customizability: The composition and structure of liposomes can be adjusted according to needs, such as altering phospholipid types or adding targeting ligands. These properties make liposomes highly valuable in developing novel drug delivery systems, serving as nucleic acid carriers for gene transfection, studying cellular uptake mechanisms and drug release kinetics, as well as developing functional food additives to improve the bioavailability of nutritional components.

MCE contains 227 liposome compounds, which is a good tool for drug delivery-related studies.

Cat. No.: HY-L252
76 compounds

Carbohydrate metabolism serves as a central hub for energy supply and biosynthesis in living organisms and plays a critical role in the onset and progression of various diseases. In recent years, studies have shown that tumor cells reprogram their energy metabolism through aerobic glycolysis (the Warburg effect) to support rapid proliferation. Immune cells also rely on specific carbohydrate metabolic pathways to regulate their activation and differentiation states, while disorders such as diabetes and metabolic syndrome arise directly from dysregulation of carbohydrate metabolism. In addition, enzymes and key metabolic nodes involved in carbohydrate metabolism have become important targets for drug discovery, and therapeutic strategies targeting glycolysis, the pentose phosphate pathway, and energy metabolism are continuously advancing the treatment of cancer and metabolic diseases. Therefore, systematic analysis of carbohydrate metabolic networks and their associated metabolites is of great significance for elucidating disease mechanisms and developing novel therapeutic approaches.

The MCE Carbohydrate Metabolism Metabolite Library is constructed based on classical carbohydrate metabolic pathways and contains 76 metabolites. It systematically integrates key metabolic networks, including glycolysis, the pentose phosphate pathway, the tricarboxylic acid (TCA) cycle, monosaccharide metabolism, and sugar acid interconversions. The library comprehensively covers core metabolic nodes from glucose uptake and utilization to energy production and biosynthesis, while also incorporating important upstream and downstream intermediates. It enables accurate representation of intracellular metabolic flux dynamics and is well suited for applications such as metabolic flux analysis, target validation, and mechanistic studies. Furthermore, it provides robust support for multi-omics integration and the development of precision intervention strategies.